MedTrace Logo

Ablation-Index Guided Scar-Mediated Ventricular Tachycardia Ablation in Patients With Ischemic Cardiomyopathy

NCT06138873 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-09-22

No results posted yet for this study

Summary

Over the last decade, radiofrequency catheter ablation (RFCA) has become an established treatment for ventricular arrhythmias (VA). Due to the challenging nature of visualizing lesion formation in real time and ensuring an effective transmural lesion, different surrogate measures of lesion quality have been used. The Ablation Index (AI) is a variable incorporating power delivery in its formula and combining it with CF and time in a weighted equation which aims at allowing for a more precise estimation of lesion depth and quality when ablating VAs. AI guidance has previously been shown to improve outcomes in atrial and ventricular ablation in patients with premature ventricular complexes (PVC). However research on outcomes following AI-guidance for VT ablation specifically in patients with structural disease and prior myocardial infarction remains sparse. The investigators aim at conducting the first randomized controlled trial testing for the superiority of an AI-guided approach regarding procedural duration.

Conditions

  • Ventricular Tachycardia
  • Ischemic Cardiomyopathy

Interventions

PROCEDURE

Ablation-index guided ventricular tachycardia ablation

As described in arms descriptions

PROCEDURE

Ventricular tachycardia ablation with no AI-guidance

As described in arms descriptions

Sponsors & Collaborators

  • University of Michigan

    collaborator OTHER

  • Medical University of South Carolina

    collaborator OTHER

  • Biosense Webster, Inc.

    collaborator INDUSTRY

  • Mayo Clinic

    collaborator OTHER

  • Brigham and Women's Hospital

    collaborator OTHER

  • Rush University Medical Center

    lead OTHER

Principal Investigators

  • Alexander Mazur, MD · Rush University Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-23
Primary Completion
2026-11-23
Completion
2027-11-23

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06138873 on ClinicalTrials.gov